These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19474480)

  • 1. Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay.
    Dahari H; Shudo E; Cotler SJ; Layden TJ; Perelson AS
    Antivir Ther; 2009; 14(3):459-64. PubMed ID: 19474480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin.
    Layden-Almer JE; Ribeiro RM; Wiley T; Perelson AS; Layden TJ
    Hepatology; 2003 Jun; 37(6):1343-50. PubMed ID: 12774013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.
    Sherman KE; Shire NJ; Rouster SD; Peters MG; James Koziel M; Chung RT; Horn PS
    Gastroenterology; 2005 Feb; 128(2):313-27. PubMed ID: 15685543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triphasic decline of hepatitis C virus RNA during antiviral therapy.
    Dahari H; Ribeiro RM; Perelson AS
    Hepatology; 2007 Jul; 46(1):16-21. PubMed ID: 17596864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon.
    Herrmann E; Lee JH; Marinos G; Modi M; Zeuzem S
    Hepatology; 2003 Jun; 37(6):1351-8. PubMed ID: 12774014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mathematical modeling of HCV infection and treatment.
    Dahari H; Shudo E; Ribeiro RM; Perelson AS
    Methods Mol Biol; 2009; 510():439-53. PubMed ID: 19009281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A perspective on modelling hepatitis C virus infection.
    Guedj J; Rong L; Dahari H; Perelson AS
    J Viral Hepat; 2010 Dec; 17(12):825-33. PubMed ID: 20723038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma HCV-RNA decline in the first 48 h identifies hepatitis C virus mono-infected but not HCV/HIV-coinfected patients with an undetectable HCV viral load at week 4 of peginterferon-alfa-2a/ribavirin therapy.
    Arends JE; Stuart JC; Baak LC; van der Ende ME; van Erpecum KJ; Simons CP; Boland GJ; van Baarle D; Hoepelman AI
    J Viral Hepat; 2009 Dec; 16(12):867-75. PubMed ID: 19457139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy.
    Tang KH; Herrmann E; Cooksley H; Tatman N; Chokshi S; Williams R; Zeuzem S; Naoumov NV
    J Hepatol; 2005 Nov; 43(5):776-82. PubMed ID: 16139918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment.
    Durante-Mangoni E; Zampino R; Portella G; Adinolfi LE; Utili R; Ruggiero G
    Clin Infect Dis; 2009 Aug; 49(4):498-506. PubMed ID: 19591593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The kinetics of hepatitis C virus infection.
    Zeuzem S
    Clin Liver Dis; 2001 Nov; 5(4):917-30. PubMed ID: 11685801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
    Buti M; Sanchez-Avila F; Lurie Y; Stalgis C; Valdés A; Martell M; Esteban R
    Hepatology; 2002 Apr; 35(4):930-6. PubMed ID: 11915041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts.
    Avidan NU; Goldstein D; Rozenberg L; McLaughlin M; Ferenci P; Masur H; Buti M; Fauci AS; Polis MA; Kottilil S
    J Acquir Immune Defic Syndr; 2009 Dec; 52(4):452-8. PubMed ID: 19797971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
    Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy.
    Pugnale P; Herrmann E; Neumann AU; Pawlotsky JM; Schalm SW; Ferrari C; Homburger Y; Zeuzem S; Negro F;
    J Hepatol; 2008 Jun; 48(6):932-8. PubMed ID: 18433918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C.
    Reau N; Satoskar R; Te H; DeVoss A; Elsen C; Reddy G; Mohanty S; Jensen D
    Am J Gastroenterol; 2011 Mar; 106(3):452-8. PubMed ID: 21063395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
    Zeuzem S; Schmidt JM; Lee JH; von Wagner M; Teuber G; Roth WK
    Hepatology; 1998 Jul; 28(1):245-52. PubMed ID: 9657119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia.
    Shire NJ; Horn PS; Rouster SD; Stanford S; Eyster ME; Sherman KE;
    Hepatology; 2006 Nov; 44(5):1146-57. PubMed ID: 17058240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.